IMODIUM COMPLETE CHEWABLE TABLETS TABLET (CHEWABLE)

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Vedd Meg Most

Letöltés Termékjellemzők (SPC)
22-05-2019

Aktív összetevők:

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

Beszerezhető a:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

ATC-kód:

A07DA53

INN (nemzetközi neve):

LOPERAMIDE, COMBINATIONS

Adagolás:

2MG; 125MG

Gyógyszerészeti forma:

TABLET (CHEWABLE)

Összetétel:

LOPERAMIDE HYDROCHLORIDE 2MG; SIMETHICONE 125MG

Az alkalmazás módja:

ORAL

db csomag:

5/10/20

Recept típusa:

OTC

Terápiás terület:

ANTIDIARRHEA AGENTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0231812001; AHFS:

Engedélyezési státusz:

CANCELLED POST MARKET

Engedély dátuma:

2014-05-21

Termékjellemzők

                                _ _
_ IMODIUM_
_®_
_ Complete _
_Page 1 of 22_
PRODUCT MONOGRAPH
IMODIUM
®
Complete
Loperamide Hydrochloride, 2 mg/ Simethicone, 125 mg
Oral antidiarrheal/antiflatulent agent
McNeil Consumer Healthcare,
Division of Johnson & Johnson Inc.
88 McNabb St.
Markham, Ontario
L3R 5L2
Date of Revision:
May 22, 2019
Submission Control No: 225986
_ _
_ IMODIUM_
_®_
_ Complete _
_Page 2 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
5
DRUG INTERACTIONS
...................................................................................................
8
DOSAGE AND ADMINISTRATION
...............................................................................
8
OVERDOSAGE
..................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 10
STORAGE AND STABILITY
.........................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 11
PART II: SCIENTIFIC INFORMATION
..............................................................................
12
PHARMACEUTICAL INFORMATION
.........................................................................
12
CLINICAL TRIALS
...........................................................................................
                                
                                Olvassa el a teljes dokumentumot
                                
                            

Dokumentumok más nyelveken

Termékjellemzők Termékjellemzők francia 22-05-2019